Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies.

CONCLUSION: PP3M was efficacious and showed no new safety concerns in patients with schizophrenia from Latin America, corroborating ROW findings. CLINICAL TRIAL REGISTRATION: NCT01515423, NCT01529515. PMID: 30994855 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30994855?dopt=Abstract

Source: Revista Brasileira de Psiquiatria - April 14, 2019 Category: Psychiatry Authors: Savitz AJ, Xu H, Gopal S, Nuamah I, Mathews M, Soares B Tags: Braz J Psychiatry Source Type: research